Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-07-15
2009-10-13
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S278000
Reexamination Certificate
active
07601725
ABSTRACT:
The present invention provides compounds having the formula:wherein R1, R2, X1, X2, L1, L2, Y and Z are as defined in classes and subclasses herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., Aurora), and thus are useful, for example, for the treatment of Aurora mediated diseases.
REFERENCES:
patent: 4146716 (1979-03-01), Cox et al.
patent: 4196207 (1980-04-01), Webber et al.
patent: 5073558 (1991-12-01), Obata et al.
patent: 5124333 (1992-06-01), Obata et al.
patent: 5141941 (1992-08-01), Fujii et al.
patent: 5187168 (1993-02-01), Primeau et al.
patent: 5227387 (1993-07-01), Dreikorn et al.
patent: 5654307 (1997-08-01), Bridges et al.
patent: 5859020 (1999-01-01), Preuss et al.
patent: 6133271 (2000-10-01), Pamukcu et al.
patent: 6166016 (2000-12-01), Okamura et al.
patent: 6169091 (2001-01-01), Cockerill et al.
patent: 6187777 (2001-02-01), Norman et al.
patent: 6284764 (2001-09-01), Kath et al.
patent: 6288078 (2001-09-01), Walsh et al.
patent: 6407124 (2002-06-01), Rawlins et al.
patent: 6414156 (2002-07-01), Chen et al.
patent: 6465449 (2002-10-01), Kath et al.
patent: 6503914 (2003-01-01), Benish et al.
patent: 6515004 (2003-02-01), Misra et al.
patent: 6534531 (2003-03-01), Kimball et al.
patent: 6541481 (2003-04-01), Kath et al.
patent: 6596744 (2003-07-01), Wagle et al.
patent: 6596746 (2003-07-01), Das et al.
patent: 6608053 (2003-08-01), Hayakawa et al.
patent: 6608056 (2003-08-01), Hayakawa et al.
patent: 6627767 (2003-09-01), Liu et al.
patent: 6660737 (2003-12-01), Almstead et al.
patent: 6706717 (2004-03-01), Barrish et al.
patent: 6720347 (2004-04-01), Rawlins et al.
patent: 6770641 (2004-08-01), Hayakawa et al.
patent: 6770663 (2004-08-01), Wagle et al.
patent: 6838547 (2005-01-01), Beria et al.
patent: 6903085 (2005-06-01), Thom et al.
patent: 2002/0022622 (2002-02-01), Wagle et al.
patent: 2002/0119970 (2002-08-01), Wagle et al.
patent: 2002/0165261 (2002-11-01), Borisy et al.
patent: 2004/0024208 (2004-02-01), Das et al.
patent: 2004/0053897 (2004-03-01), Dalton et al.
patent: 2004/0054186 (2004-03-01), Das et al.
patent: 2004/0067989 (2004-04-01), Barrish et al.
patent: 2004/0067990 (2004-04-01), Barrish et al.
patent: 2004/0073026 (2004-04-01), Das et al.
patent: 2004/0077695 (2004-04-01), Barrish et al.
patent: 2004/0077875 (2004-04-01), Das et al.
patent: 2004/0082576 (2004-04-01), Arrhenius et al.
patent: 2004/0087557 (2004-05-01), Steiner et al.
patent: 2004/0110752 (2004-06-01), Barrish et al.
patent: 2004/0122235 (2004-06-01), Polisetti et al.
patent: 2004/0171075 (2004-09-01), Flynn et al.
patent: 2004/0180906 (2004-09-01), Flynn et al.
patent: 2004/0197928 (2004-10-01), Dalton et al.
patent: 2004/0224979 (2004-11-01), Dalton et al.
patent: 2005/0014771 (2005-01-01), Hayakawa et al.
patent: 2005/0032788 (2005-02-01), Wagle et al.
patent: 2005/0070538 (2005-03-01), Cheng et al.
patent: 2005/0080054 (2005-04-01), Dalton et al.
patent: 19827611 (1997-07-01), None
patent: 356158 (1989-08-01), None
patent: 370704 (1989-11-01), None
patent: 411634 (1990-08-01), None
patent: 424125 (1990-10-01), None
patent: 447891 (1991-03-01), None
patent: 452002 (1991-03-01), None
patent: 0534341 (1992-09-01), None
patent: 1029853 (1999-12-01), None
patent: 3-63266 (1991-03-01), None
patent: 3-063271 (1991-03-01), None
patent: 3-173872 (1991-07-01), None
patent: 4-164072 (1992-06-01), None
patent: 4-235976 (1992-08-01), None
patent: 7-10712 (1995-01-01), None
patent: 11-222435 (1999-08-01), None
patent: 2002-105081 (2002-04-01), None
patent: WO 93/04583 (1993-03-01), None
patent: WO 95/19774 (1995-07-01), None
patent: WO 96/17843 (1996-06-01), None
patent: WO 97/09316 (1997-03-01), None
patent: WO 97/46560 (1997-11-01), None
patent: WO 99/40091 (1999-08-01), None
patent: WO 99/65884 (1999-12-01), None
patent: WO 00/44728 (2000-08-01), None
patent: WO 00/53185 (2000-09-01), None
patent: WO 00/53602 (2000-09-01), None
patent: WO 00/69843 (2000-11-01), None
patent: WO 00/69844 (2000-11-01), None
patent: WO 01/14333 (2001-03-01), None
patent: WO 01/32632 (2001-05-01), None
patent: WO 01/52847 (2001-07-01), None
patent: WO 01/80813 (2001-11-01), None
patent: WO 01/83456 (2001-11-01), None
patent: WO 02/18321 (2002-03-01), None
patent: WO 02/50071 (2002-06-01), None
patent: WO 02/053156 (2002-07-01), None
patent: WO 02/053158 (2002-07-01), None
patent: WO 02/053161 (2002-07-01), None
patent: WO 02/058697 (2002-08-01), None
patent: WO 02/058698 (2002-08-01), None
patent: WO 02/089809 (2002-11-01), None
patent: WO 03/009852 (2003-02-01), None
patent: WO 03/049675 (2003-06-01), None
patent: WO 03/053446 (2003-07-01), None
patent: WO 03/055491 (2003-07-01), None
patent: WO 03/064428 (2003-08-01), None
patent: WO 03/065992 (2003-08-01), None
patent: WO 03/090869 (2003-11-01), None
patent: WO 2004/002481 (2004-01-01), None
patent: WO 2004/006849 (2004-01-01), None
patent: WO 2004/029060 (2004-04-01), None
patent: WO 2004/034978 (2004-04-01), None
patent: WO 2004/035739 (2004-04-01), None
patent: WO 2004/060305 (2004-07-01), None
patent: WO 2004/060306 (2004-07-01), None
patent: WO 2004/085388 (2004-10-01), None
patent: WO 2004/110350 (2004-12-01), None
Vippagunta, et. al., Advanced Drug Delivery Reviews; 48, (2001) 3-26.
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface.
Borisy, et. al., Proceedings of the National Academy of Sciences of the United States of America, 100(13) 7977-7982.
Cecil Textbook of Medicine, 21st Edition (2000), Goldman & Bennett (Editors), W.B. Saunders Company (Publisher), Chapter 198, pp. 1060-1074.
Internal Medicine, 4th Edition, Editor-in-Chief Jay Stein, Chapters 71-72, pp. 699-715.
Bischoff et al., “A homologue ofDrosophila aurorakinase is oncogenic and amplified in human colorectal cancers”EMBO J. 1998, 17, 3052-3065.
Garcia-Bustos et al., “PIK1, an essential phosphatidylinositol 4-kinase associated with the yeast nucleus”EMBO J. 1994, 13, 2352-2361.
Hanks, S.K., Hunter, T., “Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification”FASEB J. 1995, 9, 576-596.
Hiles et al., “Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit”Cell1992, 70, 419-429.
Kimura et al., “Cell Cycle-dependent Expression and Spindle Pole Localization of a Novel Human Protein Kinase, Aik, Related to Aurora ofDrosophilaand Yeast Ipl1”J. Biol. Chem. 1997, 272, 13766-13771.
Knighton et al., “Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase”Science1991, 253, 407-414.
Kunz et al., “Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression”Cell1993, 73, 585-596.
Schumacher et al., “AIR-2: An Aurora/Ipl1-related Protein Kinase Associated with Chromosomes and Midbody Microtubules Is Required for Polar Body Extrusion and Cytokinesis inCaenorhabditis elegansEmbryos”J. Cell Biol. 1998, 143, 1635-1646.
Bohm, et al., “Uber Thieno-Verbindungen,” Pharmazie (1986) 41:23-25 (English Abstract).
Baskaran Subramanian
Lew Willard
Oslob Johan D.
Yoburn Joshua C.
Zhong Min
Choate Hall & Stewart LLP
Murray Jeffrey H
Robidoux Andrea L. C.
Sunesis Pharmaceuticals, Inc.
Wilson James O
LandOfFree
Thienopyrimidines useful as Aurora kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thienopyrimidines useful as Aurora kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thienopyrimidines useful as Aurora kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4062954